ELOX
NASDAQEloxx Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks16-40%
2025-12-072026-05-31
Mix1690d
- Insider8(50%)
- SEC Filings5(31%)
- Other3(19%)
Latest news
25 items- SECSEC Form 8-A12B filed by Eloxx Pharmaceuticals Inc.8-A12B - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECAmendment: SEC Form S-1/A filed by Eloxx Pharmaceuticals Inc.S-1/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECEloxx Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- INSIDERSEC Form 3 filed by new insider Webster Stephen W3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kjellson Nina S3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERLarge owner Coastlands Capital Lp disposed of 1,250,000 shares (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERDirector Rubin Steven D converted options into 1,875 shares, increasing direct ownership by 15% to 14,625 units (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERPresident and CEO Aggarwal Sumit exercised 472,826 shares at a strike of $0.08 and was granted 1,000,000 shares, increasing direct ownership by 737% to 1,672,756 units (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERDirector Walts Alan Edmund converted options into 1,875 shares, increasing direct ownership by 14% to 15,567 units (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- SECSEC Form DEF 14C filed by Eloxx Pharmaceuticals Inc.DEF 14C - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECSEC Form S-1 filed by Eloxx Pharmaceuticals Inc.S-1 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECSEC Form 10-Q filed by Eloxx Pharmaceuticals Inc.10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- INSIDERNew insider Domicilium Real Estate Fund Iii Lp claimed ownership of 1,407,138 shares (SEC Form 3)3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERNew insider Coastlands Capital Lp claimed ownership of 1,250,000 shares (SEC Form 3)3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- SECSEC Form 8-K filed by Eloxx Pharmaceuticals Inc.8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECSEC Form PRE 14C filed by Eloxx Pharmaceuticals Inc.PRE 14C - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- SECSEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- PREloxx Pharmaceuticals Announces Key Corporate AccomplishmentsData from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases w
- INSIDERDirector Walts Alan Edmund was granted 12,000 shares, increasing direct ownership by 1,274% to 12,942 units (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERDirector Androski Lindsay was granted 12,000 shares (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- INSIDERDirector Rubin Steven D was granted 12,000 shares (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- SECEloxx Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
- INSIDERPRESIDENT AND CEO Aggarwal Sumit was granted 165,000 shares, increasing direct ownership by 3,347% to 169,930 units (SEC Form 4)4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)
- SECSEC Form NT 10-Q filed by Eloxx Pharmaceuticals Inc.NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)
ELOX FAQ
6 questionsWhat does Eloxx Pharmaceuticals Inc. do?
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.Where does ELOX stock trade?
Eloxx Pharmaceuticals Inc. (ELOX) is listed on NASDAQ.What sector and industry is ELOX in?
Eloxx Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about ELOX?
Eloxx Pharmaceuticals Inc. has had 4 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $400.00 price target on 2021-12-17. Recent price targets range from $100.00 to $400.00.What companies are similar to ELOX?
Notable peers in the same industry include SUPN (Supernus Pharmaceuticals Inc.), ANIP (ANI Pharmaceuticals Inc.), ZYME (Zymeworks Inc.). Compare ELOX side-by-side with any of them on Quantisnow.How can I track ELOX on Quantisnow?
Quantisnow aggregates Eloxx Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELOX to receive live email and push alerts on every new disclosure.